Tarsus Pharmaceuticals

Developing innovative therapies for Demodex blepharitis and eye care

Tarsus Pharmaceuticals is focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions. The company’s lead product TP-03 is a topical ophthalmic that targets an underlying cause of blepharitis and has the potential to be the first-ever drug treatment for this condition. Tarsus’ product pipeline includes additional indications in eye care and other areas of high unmet clinical need.

IPO in 2020 (NASDAQ: TARS)
Year of Investment
Life Sciences
Irvine, California